[1] Elliott M A, Tefferi A. The molecular genetics of chronic neutrophilic leukaemia: defining a new era in diagnosis and therapy [J]. Curr Opin Hematol, 2014, 21(2): 148-154.
[2] Vardiman J, Hyjek E. World Health Organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants [J]. Hematology Am Soc Hematol Educ Program, 2011, 2011(1): 250-256.
[3] Menezes J, Cigudosa J C. Chronic neutrophilic leukemia: a clinical perspective [J]. Onco Targets Ther, 2015, 8:2383-2390.
[4] Neureiter D,Kemmerling R,Ocker M,et al. Differential diagnostic challenge of chronic neutrophilic leukemia in a patient with prolonged leukocytosis [J]. J Hematopathol, 2008, 1(1): 23-27.
[5] Gotlib J, Maxson J E, George T I, et al. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment [J]. Blood, 2013, 122(10): 1707-1711.
[6] Bain B J, Vardiman J, Thiele J. WHO classification of tumours of haematopoietic and lymphoid tissue: chronic neutrophilic leukaemia [R]. Geneva, Switzerland: WHO,2008: 38-39.
[7] Uppal G,Gong J. Chronic neutrophilic leukaemia[J]. J Clin Pathol, 2015, 68(9): 680-684.
[8] Al Ghasham N S. Neutrophilic-chronic myeloid leukemia: a case report [J]. Int J Health Sci (Qassim), 2015, 9(1): 87-90.
[9] Bain B J, Ahmad S. Chronic neutrophilic leukaemia and plasma cell-related neutrophilic leukaemoid reactions [J]. Br J Haematol, 2015, 171(3): 400-410.
[10] Nedeljkovic M, He S, Szer J, et al. Chronic neutrophilia associated with myeloma: is it clonal? [J]. Leuk Lymphoma, 2014, 55(2): 439-440.
[11] 吴玮玮, 吴学宾, 王 轩, 等. 慢性中性粒细胞白血病1例[J]. 中华内科杂志, 2015, 54(11):970-972.
[12] Yamamoto K, Nagata K, Kida A,et al. Acquired gain of an X chromosome as the sole abnormality in the blast crisis of chronic neutrophilic leukemia [J]. Cancer Genet Cytogenet, 2002, 134(1): 84-87.
[13] Elliott M A, Hanson C A, Dewald G W, et al. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature[J]. Leukemia, 2005, 19(2):313-317.
[14] Tefferi A, Elliott M A, Pardanani A. Atypical myeloproliferative disorders: diagnosis and management [J]. Mayo Clin Proc, 2006, 81(4): 553-563.
[15] James C, Ugo V, Casadevall N, et al. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects [J]. Trends Mol Med, 2005, 11(12): 546-554.
[16] Campbell L J. Cytogenetics of myeloproliferative neoplasms[J]. Methods Mol Biol, 2011, 730: 89-98.
[17] Vardiman J W, Thiele J, Arber D A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes [J]. Blood, 2009, 114(5): 937-951.
[18] Jatiani S S, Baker S J, Silverman L R, et al. Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies [J]. Genes Cancer, 2010, 1(10): 979-993.
[19] Kralovics R, Passamonti F, Buser A S, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders [J]. N Engl J Med, 2005, 352(17): 1779-1790.
[20] Jones A V, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders[J].Blood,2005,106(6):2162-2168.
[21] Levine R L, Loriaux M, Huntly B J, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia[J].Blood,2005,106(10):3377-3379.
[22] Tefferi A, Gilliland G D. Oncogenes in myeloproliferative disorders [J]. Cell Cycle, 2007, 6(5): 550-566.
[23] Hellmann A. Myeloproliferative syndromes: diagnosis and therapeutic options [J]. Pol Arch Med Wewn, 2008, 118 (12): 756-760.
[24] Erber W, Reilly J T. Chronic neutrophilic leukemia with plasma cell dyscrasia: friends or relatives? [J]. Leuk Lymphoma, 2014, 55(2): 240-242.
[25] Liongue C, Ward A C. Granulocyte colony-stimulating factor receptor mutations in myeloid malignancy [J]. Front Oncol, 2014 , 4(93): 1-7.
[26] Pardanani A, Lasho T L, Laborde R R, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia[J]. Leukemia, 2013, 27(9): 1870-1873.
[27] Maxson J E, Gotlib J, Pollyea D A, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML[J]. N Engl J Med, 2013, 368(19): 1781-1790.
[28] Makishima H,Yoshida K,Nguyen N, et al. Somatic SETBP1 mutations in myeloid malignancies [J]. Nat Genet, 2013, 45(8): 942-946.
[29] Senín A, Arenillas L, Martínez-Avilés L, et al. Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia[J]. Med Clin (Barc), 2015, 144(11): 487-490.
[30] Meggendorfer M, Bacher U, Alpermann T, et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, ASXL1 and CBL mutations[J]. Leukemia, 2013, 27(9): 1852-1860.
[31] Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia [J]. Nat Genet, 2013, 45(1): 18-24.
[32] Menezes J, Makishima H, Gomez I, et al. CSF3R T618I co-occurs with mutations of splicing and epigenetic genes and with a new PIM3 truncated fusion gene in chronic neutrophilic leukemia [J]. Blood Cancer J, 2013, 3(11): e158-161.
[33] Touw P I,Beekman R. Severe congenital neutropenia and chronic neutrophilic leukemia: an intriguing molecular connection unveiled by oncogenic mutations in CSF3R [J]. Haematologica, 2013, 98(10):1490-1492.
[34] Elliott M A, Pardanani A, Hanson C A,et al. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia [J]. Am J Hematol, 2015, 90(7): 653-656.
[35] Tefferi A, Elliott M,Pardanani A. Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice [J].Curr Opin Hematol, 2015, 22(2): 171-176.
[36] Meggendorfer M, Haferlach T, Alpermann T, et al. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia [J]. Heamotologica, 2014, 99(12): e244-246.
[37] Li B, Gale R P, Xiao Z J. Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia [J]. J Hematol Oncol, 2014, 7: 93-100.
[38] Elliott M A, Tefferi A. Chronic neutrophilic leukemia 2016: update on diagnosis, molecular genetics, prognosis, and management[J]. Am J Hematol, 2016, 91(3): 341-349.
[39] Bhm J,Schaefer H E. Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease [J]. J Clin Pathol, 2002, 55(11): 862-864.
[40] Fleischman A, Maxson J E, Luty S B, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition [J]. Blood, 2013, 122(22): 3628-3631.
[41] Kako S, Kanda Y, Sato T, et al. Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation[J]. Am J Hematol, 2007, 82(5): 386-390.
[42] Goto H, Hara T, Tsurumi H, et al. Chronic neutrophilic leukemia with congenital robertsonian translocation successfully treated with allogeneic bone marrow transplantation in a young man[J]. Inter Med, 2009, 48(7): 563-567.
[43] Zhang X Y, Pan J G, Guo J X. Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon Alfa-2b [J]. Acta Haematol, 2013, 130(1): 44-46.
[44] Jain N, Khoury J D, Pemmaraju N, et al. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement [J]. Blood, 2013, 122(19): 3387-3388.
[45] Imashuku S, Kudo N, Kubo K, et al. Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation [J]. J Blood Med, 2012, 3(7): 157-161.